Remote Temperature Monitoring of Patients At Risk for Developing Fever

Last updated: December 22, 2024
Sponsor: AION Biosystems
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer

Fever

Treatment

Remote Patient Monitoring

Clinical Study ID

NCT06752512
ELLIS001
  • Ages > 18
  • All Genders

Study Summary

The purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment. The main questions it aims to answer are:

  • does remote temperature monitoring reduce the number of days spent inpatient

  • what out-of-pocket cost can a patient expect to incur for participating in remote temperature monitoring

  • the number of billable CPT codes that will be generated by providing remote temperature monitoring

Researchers will compare compliant and non-compliant patients to assess if compliance with remote temperature monitoring is associated with a decrease in the number of days spent inpatient.

Patients will

  • wear the thermometer for the duration of their participation in the study

  • have their temperature monitored continuously

  • receive alerts on their phone when their temperature exceeds a threshold for a sustained duration, configurable by their physician

  • respond to texts or calls from remote monitors when an alert is triggered

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject is at risk of a fever post discharge.

  • Subject is ≥ 18 years or older.

  • Subject has an iOS or Android phone, or is able to operate an AION providedsmartphone device.

  • Subject is willing to install the TempShield app on his/her phone.

  • Subject is willing to allow AION to send text reminders to take temperature orcomplete surveys.

  • Subject is willing to take an oral temperature as directed by their care plan.

  • Subject is willing to configure the phone to ensure these notifications aredelivered, even when phone is in a "no notification" mode.

  • Subject or subject caretaker is able and willing to complete subject surveys.

  • Subject is willing and able to provide written informed consent in English.

  • Subject is willing and able to comply with all program procedures, requirements,assessments, visits, and complete questionnaires.

  • English speakers

Exclusion

Exclusion Criteria:

  • Unable to provide informed consent

  • Subjects with a history of Medical Adhesive-Related Skin Injury (MARSI)

  • Subjects with no available placement that avoids open wounds or traumatized skin (burns. Blisters. Etc.)

  • Non-English speakers: The mobile application is only currently available in English.Future development will include other languages.

  • Subjects receiving prophylactics that could induce fever.

  • Subjects with a silicon allergy

  • Subject does not have iOS or Android phone, and is unable to operate an AIONprovided smartphone device.

  • Subjects who are not willing to take an oral temperature per their care plan.

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: Remote Patient Monitoring
Phase:
Study Start date:
August 09, 2023
Estimated Completion Date:
January 31, 2025

Connect with a study center

  • Ellis Hospital

    Schenectady, New York 12308
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.